## Tables

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Statin-Use |  | Non-Use |  | Test Statistic |
|  | **(N=499)** | **%** | **(N=272)** | **%** | **p-value** |
| Age (years) Mean (SD) | 58.2 **66.0** 75.0 |  | 59.0 **69.0** 77.0 |  | 0.067 |
| Female | 96/499 | 19.2 | 84/272 | 30.9 | < 0.001 |
| Male | 403/499 | 80.8 | 188/272 | 69.1 |   |
| Amputation Level |  |  |  |  | 0.154 |
| BKA | 295/499 | 59.1 | 179/272 | 65.8 |  |
| TKA | 21/499 | 4.21 | 12/272 | 4.41 |  |
| AKA | 183/499 | 36.7 | 81/272 | 29.8 |  |
| Peripheral Arterial Disease (PAD) | 266/499 | 53.3 | 148/272 | 54.4 | 0.769 |
| Diabetes mellitus (DM) | 336/499 | 67.3 | 149/272 | 54.8 | < 0.001 |
| Hypertension (HTN) | 268/499 | 53.7 | 130/272 | 47.8 | 0.116 |
| Hyperlipidaemia | 118/499 | 23.6 | 52/272 | 19.1 | 0.147 |
| Ischaemic Heart Disease (IHD) | 171/499 | 34.3 | 78/272 | 28.7 | 0.113 |
| Atrial Fibrillation (AF) | 69/499 | 13.8 | 38/272 | 14.0 | 0.956 |
| Heart Failure (HF) | 41/499 | 8.22 | 25/272 | 9.19 | 0.644 |
| Cerebrovascular disease (TIA/Stroke) | 70/499 | 14.0 | 37/272 | 13.6 | 0.870 |
| Renal Failure |  |  |  |  | 0.038 |
| Normal-Moderate (30<eGFR<60) | 431/499 | 86.4 | 220/272 | 80.9 |  |
| Moderate-Severe(15<eGFR<30) | 53/499 | 10.6 | 34/272 | 12.5 |  |
| End-Stage(eGFR<15) | 15/499 | 3.01 | 18/272 | 6.62 |  |
| Chronic Obstructive Pulmonary Disease (COPD) | 78/499 | 15.6 | 41/272 | 15.1 | 0.838 |
| Malignancy | 22/499 | 4.41 | 26/272 | 9.56 | 0.005 |
| Psychiatric History | 163/499 | 32.7 | 67/272 | 24.6 | 0.020 |
| Alcohol/Drug Misuse | 28/499 | 5.61 | 17/272 | 6.25 | 0.718 |
| Cognitive Impairment | 8/499 | 1.60 | 11/272 | 4.04 | 0.037 |
| Pre-MLA Functional Grade Mean (SD) | 4.0 **4.0** 5.0 | 0.0 | 4.0 **4.0** 5.0 | 0.0 | 0.126 |
| Aspirin | 281/499 | 56.3 | 45/272 | 16.5 | < 0.001 |
| Clopidogrel | 177/499 | 35.5 | 23/272 | 8.5 | < 0.001 |
| Ticagrelor | 5/499 | 1.00 | 1/272 | 0.37 | 0.345 |
| Warfarin | 52/499 | 10.4 | 27/272 | 9.9 | 0.829 |
| NOAC/DOAC | 57/499 | 11.4 | 17/272 | 6.25 | 0.020 |
| Oral Hypoglycaemic | 195/336 | 39.1 | 35/149 | 12.9 | < 0.001 |
| Insulin | 198/336 | 39.7 | 37/149 | 13.6 | < 0.001 |
| Antihypertensive | 196/499 | 39.3 | 44/272 | 16.2 | < 0.001 |
| Antidepressant | 177/499 | 35.5 | 52/272 | 19.1 | < 0.001 |

Table 1: Patient characteristics grouped by statin-use versus non-use.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total (N=771) | Statin-Use(N=499) | Non-Use(N=272) | Test Statistic p value |
|  |
| Prosthetic Mobility |
| ****SIGAM Score**** |  |  |  | 0.0881 |
| F | - | - | - |  |
| E | 7 (0.9%) | 6 (1.2%) | 1 (0.4%) |  |
| D | 378 (49.0%) | 259 (51.9%) | 119 (43.8%) |  |
| C | 270 (35.0%) | 169 (33.9%) | 101 (37.1%) |  |
| B | 32 (4.2%) | 18 (3.6%) | 14 (5.1%) |  |
| A | 84 (10.9%) | 47 (9.4%) | 37 (13.6%) |  |
| ****Independent Prosthetic Mobility (IPM)**** |  |  |  | 0.0171 |
| IPM | 385 (49.9%) | 265 (53.1%) | 120 (44.1%) |  |
| No IPM | 386 (50.1%) | 234 (46.9%) | 152 (55.9%) |  |
| Timed-Up-Go (TUG) |  | 29.4 (18.9) | 33.2 (23.4) | 0.040 |
| 2-Minute Distance |  | 65.3 (33.4) | 60.4 (32.2) | 0.073 |
|  |  | **Survival** |  |  |
| ****Time after MLA (years)**** | No. of Deaths | No at Risk[%Survival(95%CI) | No at Risk[%Survival(95%CI) | <0.001 |
| ****1 Year**** | 53 | 480 [96.4 (94.8-98.0)] | 235 [87.0 % (83.1 -91.1)] |  |
| ****2 Years**** | 70 | 421 [88.9 (86.1-91.7)] | 188 [74.5 % (69.5-79.9 )] |  |
| ****3 Years**** | 56 | 369 [82.6 (79.3-86.0)] | 134 [63.0 % (57.3-69.3)] |  |
| ****4 Years**** | 54 | 303 [74.1 (70.2-78.3)] | 100 [53.7 % (47.6-60.5)] |  |
| ****5 Years**** | 42 | 244 [66.4 (62.1-71.0)] | 78 [46.9 % (40.6 -54.1)] |  |
| ****6 Years**** | 43 | 189 [57.8 (53.2-62.9)] | 58 [38.1 % (31.9-45.6)] |  |
| ****7 Years**** | 33 | 140 [49.8 (44.9-55.1)] | 45 [32.8 % (26.7-40.4)] |  |

 Table 2: Prosthetic mobility and survival grouped by statin-use versus non-use.